Home » BOSTON SCIENTIFIC SLIPS TO LOSS IN Q2 HURT BY CHARGES ON GUIDANT ACQUISITION
BOSTON SCIENTIFIC SLIPS TO LOSS IN Q2 HURT BY CHARGES ON GUIDANT ACQUISITION
Thursday, Boston Scientific Corp., medical device company, revealed second quarter financial results, reporting a net loss primarily from charges related to the acquisition of Guidant Corp. The company, however, reported revenues exceeding the $2 billion mark and said it was set to achieve annual sales of approximately $9 billion with an EBITDA, prior to special charges and stock compensation expenses, of approximately $2.9 billion. Trading Markets (http://www.tradingmarkets.com/tm.site/news/TOP%20STORY/321677/)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May